The expression of RUNX3 gene in renal cell cancer and its clinical relevance with serum vascular endothelial growth factor
| Autor: | Kalpesh Parmar, Arup K. Mandal, Sharwan Kumar Singh, Shalmoli Bhattacharya, Mamta Singla |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Surrogate endpoint business.industry medicine.medical_treatment Cancer medicine.disease Nephrectomy Vascular endothelial growth factor chemistry.chemical_compound chemistry Renal cell carcinoma Internal medicine Parenchyma medicine Histopathology Clinical significance business |
| Zdroj: | International Journal of Molecular and Immuno Oncology. 2:73 |
| ISSN: | 2456-3994 |
| Popis: | Background: Latest advances indicate that RUNX3 is a candidate tumor suppressor in several types of human cancers, including renal cell cancer.However, its definitive role is not yet established. Vascular endothelial growth factor (VEGF) has been widely studied as a surrogate marker ofangiogenic activity and prognostic marker in renal cancer for monitoring treatment response and detection of early relapse. The aim of the study wasto examine the clinical significance of RUNX3 expression and serum VEFG in series of renal cancer patients using quantitative real-time polymerasechain reaction and standard enzyme-linked immunosorbent assay kit and find its correlation with renal cancer stage, grade, and histopathology.Materials and Methods: We reviewed our prospectively collected renal cancer database of 47 patients. All patients were evaluated preoperativelyand staged and underwent partial or radical nephrectomy as per the feasibility criteria. RUNX 3 expression in tumor tissue and adjoining parenchymawas sampled in all patients, and serum levels of VEGF were measured in pre-and post-operative period on day 7 and day 30 after surgery. 10age- and sex-matched healthy volunteers served as control group. Results: We observed that RUNX3 gene expression was significantly lower intumor tissue than in normal renal parenchyma of a renal cancer patient. The serum VEGF levels were significantly increased in patients with renalcell carcinoma (RCC) compared to normal healthy volunteers and showed decreasing trend after the surgery. Loss of RUNX3 gene expressionand higher VEGF levels strongly correlated with high-grade tumors; however, it was not related to tumor size and histopathology. There was nocorrelation of RUNX 3 with VEGF levels in RCC patients. Conclusion: The results of this study showed that renal cancer patients had increasedVEGF levels which were effectively alleviated by curative resection. Lower expression of RUNX3 in renal cancer suggests its tumor suppressiverole and new insights into targeted therapies linking RUNX3 gene may have some diagnostic and therapeutic implications in RCC patients. We didnot find any correlation between RUNX3 gene and serum VEGF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|